Singer Jesy Nelson recently shared an emotional update regarding the complications she is experiencing in her pregnancy with twin babies. Former Little Mix singer Jesy, who is having twins with partner Zion Foster, announced that she has been diagnosed with pre-twin-to-twin transfusion syndrome (pre-TTTS). The condition, which is present in pregnancies involving twins with a shared placenta, has serious risks involved and needs intense medical supervision. As Nelson embarks on this difficult journey, her story enlightens us about a rare but dangerous condition many expectant parents may not know much about.
Twin-to-twin transfusion syndrome is a rare but dangerous condition that arises in monochorionic twin pregnancies, in which identical twins share a single placenta. The placenta supplies the developing babies with oxygen, nutrients, and blood flow, but in TTTS, there is an imbalance of blood vessels that interconnect the twins, and thus the vital resources are not evenly distributed. One twin, or the donor twin, shares excess blood with the other, referred to as the recipient twin. This leads to one baby becoming malnourished and possibly anemic, and the other in danger of heart problems due to too much blood.
Nelson described her diagnosis in a heartfelt Instagram video, explaining that she is currently in the pre-stage of TTTS and undergoing frequent monitoring. "I am being scanned twice a week, and each time, things have gotten a little worse," she shared, expressing her fears and hopes for the health of her babies.
If left untreated, TTTS can have devastating consequences. Medical research indicates that:
TTTS usually advances in stages, beginning with minimal changes in fluid levels and worsening as one twin continues to get an unequal share of blood. In extreme cases, fetal laser surgery, referred to as the Solomon technique, can be employed to divide the blood vessels and balance the twins.
Identical twins may develop differently, and their own unique form of placental sharing can have a dramatic effect on pregnancy risk. Jesy Nelson's twins are considered monochorionic diamniotic (mono/di), which means they share a placenta but have two amniotic sacs. This is the type of pregnancy in about 70% of identical twin pregnancies and carries an increased risk of complications like TTTS, umbilical cord entanglement, and growth restriction.
Conversely, dichorionic diamniotic (di/di) twins both have a separate placenta and amniotic sac, which greatly diminishes the threat of TTTS. Twin pregnancy type is normally identified by early ultrasound, with physicians being able to track future complications from inception.
Twin pregnancies, even without the presence of TTTS, entail a variety of health risks to the mother as well as infants:
Over 60% of twin pregnancies end in premature delivery, with birth usually taking place before 37 weeks. Premature infants can have immature organs and need neonatal intensive care (NICU) assistance to assist with breathing, feeding, and infection fighting.
Pregnant women with multiples are at increased risk of having high blood pressure during pregnancy. This, if left untreated, can result in preeclampsia, a serious complication of pregnancy that can result in damage to organs, preterm labor, and in some cases, maternal or fetal death.
Pregnant women carrying multiples are twice as likely to experience anemia, a condition where the body does not produce enough healthy red blood cells. This can lead to fatigue, dizziness, and complications during delivery.
According to John Hopkins Medicine, multiple birth babies are twice as likely to have congenital abnormalities compared to single births. These can include heart defects, neural tube defects, and gastrointestinal issues.
When twins have to share a placenta, they are more likely to have polyhydramnios (excess amniotic fluid) or oligohydramnios (not enough amniotic fluid). Both result in distress to the babies during fetal development and can result in premature labor.
Twins are at increased risk of excessive postpartum hemorrhage because their uterus is larger and there are greater blood supply needs.
Jesy Nelson's openness about her challenging experience is raising awareness for TTTS, a condition that few individuals—let alone expectant mothers and fathers—might be aware of. Through her tearful video, Nelson stressed the significance of knowing about twin pregnancies aside from the thrill of having multiples. "We had no idea that this type of thing occurs when you're having twins. We just desperately want to make people aware of this because there are so many people who aren't aware."
Her case reminds us of the intricacies involved in twin pregnancy and the significance of early identification and medical management. For mothers carrying twins, frequent ultrasounds and vigilance can become a life-and-death issue for early detection and better outcomes of both babies.
Through constant medical attention and care, she and her partner Zion Foster remain positive and get ready for their babies to be born. In other parents whose situations are no different, the story of Nelson highlights awareness, medical progress, and emotional encouragement in handling complicated pregnancies.
The expecting parents of twin siblings are advised to discuss TTTS screening and possible interventions with their physicians to give their babies the best chance.
Credit: iStock
A key chemical used in many gel nail polish products has been banned in England, Wales and Scotland.
The “gel nail ban” applies to one ingredient — Trimethylbenzoyl Diphenylphosphine Oxide, commonly known as TPO. It is used in some gel manicures to help the polish achieve a glossy finish and cure properly.
TPO (Trimethylbenzoyl Diphenylphosphine Oxide) is a photoinitiator commonly used in UV- and LED-cured nail products. It makes the varnish more durable and helps it hold its color for longer.
The European Union banned TPO in cosmetic products from September 1, 2025. In the UK, the ban came into effect on August 15.
The ban means manufacturers can no longer sell new products containing TPO. However, salons can continue to offer gel manicures using existing TPO-containing products until February 14, 2027, or until their stocks run out.
Nail technicians will not be able to purchase new stock containing TPO. TPO-containing products continue to be used in the US, Australia and Asia.
The ban follows several animal studies that linked TPO to long-term fertility damage and reproductive issues.
Caroline Rainsford, Director of Science at The Cosmetic, Toiletry and Perfumery Association (CTPA), said the EU ban was based on the chemical's hazardous properties and how a substance might behave in a “worst-case” situation when the body is exposed to a very large amount.
“This is not how TPO is used in cosmetics. The amount of this ingredient used in nail products is over a thousand times less than the amount which could have any negative effect on fertility, and these products are applied to the nail, so the potential for the ingredient to be absorbed into our bodies is even smaller,” Rainsford was quoted as saying in media reports.
TPO is used only in some gel polishes and is not found in traditional air-dried nail polishes. There are already TPO-free gels on the market, and many salons use these products. While some alternatives may belong to the same chemical family, different compounds have different safety ratings.
TPO-free gel systems now use alternative photoinitiators that meet regulatory standards while still delivering similar results.
TPO-free options are available across:
Credit: iStock
The UK Health Security Agency (UKHSA) has declared a national outbreak of Salmonella in the UK, with health officials suspecting a possible link to imported eggs.
According to the UKHSA, 207 confirmed cases were detected between August 11, 2025, and August 1, 2026, with the majority reported in 2026. Of those affected, 38% were admitted to hospital, and one person has died.
Cases have been reported across the UK:
Among cases in England, London reported 47 cases, the highest number, followed by Yorkshire and the Humber with 38 cases.
The UKHSA identified an increase in Salmonella Enteritidis infections caused by a single strain through whole-genome sequencing (WGS) data.
The agency has launched an investigation to identify the source of the outbreak. Initial findings suggest that the outbreak may be linked to eggs imported from outside the UK. However, the source has not been definitively established, and investigations are continuing.
Dr Kathleen O'Reilly, Associate Professor at the London School of Hygiene & Tropical Medicine, said the investigation involves identifying additional cases and examining possible common sources of infection.
Dr Damien Tully, Associate Professor at the Medical Research Council at LSHTM's Uganda Research Unit, added that the number of confirmed cases is likely to be “just the tip of the iceberg.”
Salmonella is a bacterial infection that commonly causes diarrhea and gastrointestinal illness.
Common symptoms include:
Salmonella is generally a self-limiting infection. However, young children, older adults and people with weakened immune systems can develop more severe complications.
These may include bloodstream infections, infections at other sites, sepsis and multiorgan failure.
The UKHSA stated that Salmonella Enteritidis is the most common Salmonella serovar in England and a leading cause of salmonellosis.
Like other non-typhoidal Salmonella infections, it can spread through contaminated food, including:
The bacteria can also spread through contact with contaminated environments or from person to person.
Dr O'Reilly advised fully cooking eggs before eating them and maintaining good food hygiene.
Key precautions include:
People who develop diarrhea or stomach cramps should rest and drink plenty of fluids. Young children, older adults and other vulnerable people who become ill should seek medical advice.
The US is also experiencing a Salmonella outbreak linked to eggs. The US Food and Drug Administration (FDA) upgraded the recall to its highest risk level and classified nearly 1.6 million dozen eggs as “Class I.” The agency defines a Class I recall as a situation in which there is a reasonable probability that exposure to the affected product could cause serious adverse health consequences or death.
The FDA said illness usually occurs 12 to 72 hours after consuming food contaminated with Salmonella, with symptoms typically lasting four to seven days.
Credit: AI
For people living with alopecia areata, hair loss can be unpredictable, persistent, and difficult to treat. Now, amid lack of a definitive cure, a medicine originally developed for inflammatory diseases such as rheumatoid arthritis, is showing striking results in patients with severe alopecia areata.
Two large Phase III clinical trials involving 1,399 adults and adolescents found that the drug upadacitinib significantly improved scalp hair regrowth compared with placebo. The trial’s findings were published in JAMA Dermatology.
The results are both striking and promising as alopecia areata is an autoimmune condition, in which the immune system mistakenly attacks hair follicles.
Upadacitinib, sold under the brand name Rinvoq, belongs to a class of medicines called JAK inhibitors.
JAK proteins help transmit signals that are involved in immune and inflammatory responses. In alopecia areata, abnormal immune response contributes to the attack on hair follicles.
By blocking JAK1 signaling, upadacitinib can slow down some of these immune responses, potentially allowing damaged or suppressed hair follicles to resume producing hair for some time.
The drug is already used for other autoimmune conditions including rheumatoid arthritis, Crohn's disease and ulcerative colitis.
Its potential use in alopecia is an example of drug repurposing, where an existing medicine gets used for a completely different disease.
Also read: Going Slow & Steady Really Help With Sustainable Weight Loss? New Study Challenges The Norm
The Phase III programme included two parallel trials, UP-AA1 and UP-AA2, involving adults and adolescents with severe alopecia areata.
After 24 weeks, about 45% of patients taking 15 mg of upadacitinib achieved at least 80% scalp hair coverage. More than 54% of those taking 30 mg reached the same threshold.
In comparison, only about 2% of placebo recipients achieved that level of regrowth.
Researchers also reported improvements in eyebrow and eyelash hair and indirectly in quality of life
Strikingly, benefits were seen in people with severe disease, rather than only those with a few small bald patches. Severe alopecia areata in the trials was defined as hair loss affecting at least half of the scalp.
Also read: Meniscus Tears: Why Runners & Athletes Shouldn't Ignore This Common Knee Injury
Alopecia areata currently has no guaranteed permanent cure. And this trial does not mean that the condition can be cured.
The disease can follow a relapsing and unpredictable course, with hair growing back and then falling out again.
The new findings show that upadacitinib can promote substantial hair regrowth while patients are receiving treatment. They do not prove that the underlying autoimmune disease can be permanently eliminated.
There are already approved JAK inhibitors for alopecia areata, including baricitinib, ritlecitinib and deuruxolitinib, so upadacitinib would not be the first drug in this category.
The safety findings in the trials were consistent with the known safety profile of upadacitinib, and researchers reported no new safety concerns during the study period.
Common adverse events included upper respiratory infections, acne, increased creatine phosphokinase and nasopharyngitis.
But JAK inhibitors are powerful medicines that regulates immune system and are not something people should take simply because they are experiencing hair loss. Their risks and benefits need to be assessed by a doctor.
© 2024 Bennett, Coleman & Company Limited